Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress

Parallel Session 4416

Pathways to Parkinson’s Disease

Wednesday, October 7, 2026
14:00 - 15:30 | Conference Room North 202, Level 2

In this session, the faculty will provide an update on pathogenic causes of Parkinson's disease as well as their interplay. Recent data on the role of alpha-synuclein polymorphs, LRRK2-Rab signaling and inflammation in the etiology of Parkinson's disease will be discussed. Updates on therapy targets and clinical trials in Parkinson’s disease related to these areas will be discussed.

Chairs:

Per Borghammer, Denmark
Chin-Hsien Lin, Taiwan

Presenters:

a-Synuclein Polymorphs and Their Spread in a-Synucleinopathies
Xiaobo Mao, USA

LRRK2: Pathways to Parkinson’s Disease

Neuroinflammation and Parkinson’s Disease

Neuroinflammation and Parkinson’s Disease
Jia-wei Zhou

CSPC Liaison(s):

Per Svenningsson, Sweden

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Summarize evidence on alpha-synuclein polymorphs and their spreading in the parkinsonian brain
  2. Recognize how LRRK2 mutations may cause Parkinson’s disease
  3. Discuss the importance of various inflammatory processes in the etiology of Parkinson's disease and potential therapy targets

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Intermediate / Experienced